A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI).

What Was Tested

Researchers studied NAD+ in this randomized controlled trial publication.

Intensive insulin therapy is the gold standard by which Type 1 diabetes is treated.

This concept is reinforced by the results of a recent meta-analysis of the use of NA in patients with recent-onset Type 1 diabetes.

Who Took Part

The study group was 74 patients.

The age groups tagged for this paper are young children, children, teenagers and adults, both men and women.

Response to therapy was monitored throughout the study by investigating the occurrence of clinical (complete) remission defined, according to the recommendations of the International Diabetes Immunotherapy Group, as restoration of normal fasting and post-prandial blood glucose without any insulin administration for more than 2 weeks.

How the Study Was Run

In design terms this was a randomized and double-blind study.

The patients were allocated by chance, so the NAD+ group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received NAD+.

Intensive insulin therapy was carried out in order to optimize metabolic control as soon as possible after diagnosis and to maintain blood glucose level as near to normal as possible.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin, Niacinamide and Sample Size.

What This Means in Plain Language

The paper is a randomized and double-blind study of NAD+ in 74 patients.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1999 (Diabetes/metabolism research and reviews), a journal based in England.

More context: the NAD+ compound page, all human trials.